Tom Loosli
- PhD students representative
- Institute of Medical Virology
- Department of Infectious Diseases and Hospital Epidemiology
Navigation auf uzh.ch
Is Dolutegravir-Based Combination Antiretroviral Therapy Evolution Proof in Sub-Saharan Africa
Loosli T, Hossmann S, Ingle SM, Okhai H, Kusejko K, Mouton J, Bellecave P, van Sighem A, Stecher A, d’Arminio Monforte A, Gill MJ, Sabin CA, Maartens G, Günthard HF, Sterne JAC, Lessells R, Egger M, Kouyos R (2023).
HIV-1 drug resistance in people on dolutegravir-based antiretroviral therapy: a collaborative cohort analysis (https://doi.org/10.1016/S2352-3018(23)00228-X)
The Lancet HIV, October 2023